Pharmaceutical

MSD’s Welireg secures FDA approval for renal cell carcinoma

This is the second FDA approval for MSD’s HIF-2α inhibitor following a 2021 approval to treat von Hippel-Lindau disease.

Dec 16, 2023 - 18:00
MSD’s Welireg secures FDA approval for renal cell carcinoma
This is the second FDA approval for MSD’s HIF-2α inhibitor following a 2021 approval to treat von Hippel-Lindau disease.
Read the original article

Tags:

Previous Article

Biden shakes up US drug pricing landscape with inflation-related penalties 

Next Article

Biovac receives IFC loan for vaccine manufacturing in Africa

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: British Columbia to bar Americans from buying Ozempic over supply concerns

STAT+: British Columbia to bar Americans from buying Oz...

Mar 30, 2023

STAT+: Congress is launching a tobacco harm reduction caucus. Its biggest supporter so far? Philip Morris

STAT+: Congress is launching a tobacco harm reduction c...

Apr 13, 2023

Halia plans two trials testing its anti-inflammatory lead candidate

Halia plans two trials testing its anti-inflammatory le...

Aug 22, 2023